PDCD1 and neoplasm: For blocking antibodies, such as the ones targeting PD‐1 and PD‐L1 which are not tumour‐specific, the cytotoxicity brought about by antibody‐dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP) should be averted (Boulard et al., 2022).